Further understanding of the functions of LAMP2 and its pathways in myeloma pathogenesis is important to elucidate whether lysosomal disruption could be a novel therapeutic strategy for the treatment of MM patients with LAMP2 over-expression and lysosomal abnormalities. This evidence concerns the gene LAMP2 and Miyoshi myopathy.